SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.11-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (5988)3/21/2002 4:00:33 PM
From: Biomaven  Read Replies (3) of 52153
 
DAK,

at best it may be used WITH chemo

My belief is that it remains very much an open question whether the right anti-angiogenesis drug(s) might eventually control cancer without chemo.

So I'd say your "at best" is too harsh.

All this is of course a very different issue than whether ENMD is a good investment or not. I haven't owned ENMD for a while, but I do keep an eye on them.

Note that it has now unexpectedly been discovered that Herceptin has some anti-angiogenic properties:

Message 17224658

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News